Boston Scientific Corp, a medical device maker, provided a cautious outlook for 2026, forecasting modest revenue growth and profit slightly below Wall Street expectations. This announcement caused the company’s shares to plummet more than 11% in premarket trading, despite a strong fourth-quarter performance.
The company projected adjusted earnings per share for 2026 to be in the range of $3.43 to $3.49, with the midpoint at $3.46 falling short of the average analyst estimate of $3.47 per share. Additionally, Boston Scientific expects organic revenue growth of 10% to 11% for 2026, a deceleration from the 15.8% growth recorded in 2025. This subdued outlook comes as the Massachusetts-based company prepares to integrate its recent $14.5 billion acquisition of Penumbra, which was announced last month.
Despite the cautious guidance, Boston Scientific’s fourth-quarter results exceeded analyst expectations. The company reported adjusted earnings of 80 cents per share, surpassing the consensus estimate of 78 cents, while revenue of $5.29 billion slightly edged past forecasts of $5.28 billion.
Looking ahead to the first quarter of 2026, Boston Scientific anticipates adjusted earnings of 78 cents to 80 cents per share, slightly lower than the analyst consensus of 79 cents.
Overall, while the company’s fourth-quarter performance was strong, the conservative forecast for 2026 overshadowed these results. Investors will be closely monitoring how Boston Scientific navigates the integration of Penumbra and manages to achieve its revenue and profit targets in the coming year.
This article was reported by Kamal Choudhury in Bengaluru and edited by Tasim Zahid.
